SG11201600666SA - Medicament comprising anti-phospholipase d4 antibody - Google Patents
Medicament comprising anti-phospholipase d4 antibodyInfo
- Publication number
- SG11201600666SA SG11201600666SA SG11201600666SA SG11201600666SA SG11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA SG 11201600666S A SG11201600666S A SG 11201600666SA
- Authority
- SG
- Singapore
- Prior art keywords
- phospholipase
- medicament
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013158258 | 2013-07-30 | ||
PCT/JP2014/070661 WO2015016386A1 (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201600666SA true SG11201600666SA (en) | 2016-02-26 |
Family
ID=51493000
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600666SA SG11201600666SA (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
SG10201800592SA SG10201800592SA (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201800592SA SG10201800592SA (en) | 2013-07-30 | 2014-07-30 | Medicament comprising anti-phospholipase d4 antibody |
Country Status (17)
Country | Link |
---|---|
US (2) | US20160168266A1 (en) |
EP (1) | EP3027656B1 (en) |
JP (3) | JP6431523B2 (en) |
KR (1) | KR102367760B1 (en) |
CN (1) | CN105745226B (en) |
AU (1) | AU2014297217B2 (en) |
BR (1) | BR112016002001B1 (en) |
CA (1) | CA2919736C (en) |
DK (1) | DK3027656T3 (en) |
ES (1) | ES2736324T3 (en) |
HU (1) | HUE044469T2 (en) |
MX (1) | MX2016001193A (en) |
PL (1) | PL3027656T3 (en) |
RU (1) | RU2709741C2 (en) |
SG (2) | SG11201600666SA (en) |
TR (1) | TR201910330T4 (en) |
WO (1) | WO2015016386A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102098413B1 (en) * | 2012-01-31 | 2020-04-07 | 에스비아이 바이오테크 가부시키가이샤 | Anti-phospholipase d4 antibody |
WO2018013917A1 (en) * | 2016-07-15 | 2018-01-18 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
JP7140367B2 (en) * | 2018-05-31 | 2022-09-21 | 国立大学法人 東京大学 | Analysis of soluble TLR7 in human-derived samples |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2149329C (en) * | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
EP1107978A1 (en) * | 1998-08-24 | 2001-06-20 | Alphagene, Inc. | Secreted proteins and polynucleotides encoding them |
AU2002239505A1 (en) * | 2000-12-07 | 2002-06-18 | Millennium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of viral disease using 55092 |
JP2013052781A (en) | 2011-09-05 | 2013-03-21 | Tokai Rika Co Ltd | Vehicle mirror device |
KR102098413B1 (en) * | 2012-01-31 | 2020-04-07 | 에스비아이 바이오테크 가부시키가이샤 | Anti-phospholipase d4 antibody |
-
2014
- 2014-07-30 AU AU2014297217A patent/AU2014297217B2/en active Active
- 2014-07-30 SG SG11201600666SA patent/SG11201600666SA/en unknown
- 2014-07-30 EP EP14761423.4A patent/EP3027656B1/en active Active
- 2014-07-30 TR TR2019/10330T patent/TR201910330T4/en unknown
- 2014-07-30 BR BR112016002001-4A patent/BR112016002001B1/en active IP Right Grant
- 2014-07-30 CN CN201480047721.6A patent/CN105745226B/en active Active
- 2014-07-30 DK DK14761423.4T patent/DK3027656T3/en active
- 2014-07-30 ES ES14761423T patent/ES2736324T3/en active Active
- 2014-07-30 CA CA2919736A patent/CA2919736C/en active Active
- 2014-07-30 HU HUE14761423 patent/HUE044469T2/en unknown
- 2014-07-30 PL PL14761423T patent/PL3027656T3/en unknown
- 2014-07-30 MX MX2016001193A patent/MX2016001193A/en unknown
- 2014-07-30 WO PCT/JP2014/070661 patent/WO2015016386A1/en active Application Filing
- 2014-07-30 JP JP2016503264A patent/JP6431523B2/en active Active
- 2014-07-30 RU RU2016106708A patent/RU2709741C2/en active
- 2014-07-30 SG SG10201800592SA patent/SG10201800592SA/en unknown
- 2014-07-30 KR KR1020167002746A patent/KR102367760B1/en active IP Right Grant
- 2014-07-30 US US14/908,004 patent/US20160168266A1/en not_active Abandoned
-
2018
- 2018-11-01 JP JP2018206702A patent/JP2019014759A/en not_active Ceased
-
2019
- 2019-09-25 JP JP2019173621A patent/JP6843449B2/en active Active
-
2020
- 2020-12-18 US US17/127,202 patent/US20210130493A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN105745226B (en) | 2020-03-06 |
PL3027656T3 (en) | 2019-10-31 |
JP6431523B2 (en) | 2018-11-28 |
RU2016106708A3 (en) | 2018-03-30 |
WO2015016386A1 (en) | 2015-02-05 |
CA2919736A1 (en) | 2015-02-05 |
EP3027656A1 (en) | 2016-06-08 |
ES2736324T3 (en) | 2019-12-27 |
BR112016002001A2 (en) | 2017-08-29 |
KR20160034934A (en) | 2016-03-30 |
BR112016002001B1 (en) | 2023-04-25 |
CN105745226A (en) | 2016-07-06 |
EP3027656B1 (en) | 2019-06-26 |
JP2019214621A (en) | 2019-12-19 |
SG10201800592SA (en) | 2018-03-28 |
JP6843449B2 (en) | 2021-03-17 |
US20210130493A1 (en) | 2021-05-06 |
HUE044469T2 (en) | 2019-10-28 |
RU2709741C2 (en) | 2019-12-19 |
CA2919736C (en) | 2022-03-22 |
MX2016001193A (en) | 2016-05-26 |
TR201910330T4 (en) | 2019-07-22 |
KR102367760B1 (en) | 2022-02-24 |
RU2016106708A (en) | 2017-09-01 |
JP2019014759A (en) | 2019-01-31 |
US20160168266A1 (en) | 2016-06-16 |
AU2014297217B2 (en) | 2020-01-16 |
JP2016534022A (en) | 2016-11-04 |
AU2014297217A1 (en) | 2016-02-18 |
DK3027656T3 (en) | 2019-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201905426B (en) | Drug combinations | |
SG10201708409VA (en) | Medicament device | |
AU351520S (en) | Inhaler | |
HRP20180684T1 (en) | Drug combination | |
ZA201506252B (en) | Syringe | |
AU352076S (en) | Inhaler | |
HUE038547T2 (en) | Inhaler | |
PL2978481T3 (en) | Inhaler | |
LT3632373T (en) | Inhaler | |
GB201300706D0 (en) | Antibody | |
HUE053417T2 (en) | Inhaler | |
HK1219961A1 (en) | Human anti-ifn-alpha antibodies | |
LT3035887T (en) | Inhaler | |
PL3016977T3 (en) | Human anti-il-32 antibodies | |
EP2978473A4 (en) | Auto-retractible syringe | |
SG11201600666SA (en) | Medicament comprising anti-phospholipase d4 antibody | |
GB201320786D0 (en) | Medicament | |
GB201301845D0 (en) | Antibody delivery | |
GB201316662D0 (en) | Pharmaceutical Combination | |
GB201310496D0 (en) | Pharmaceutical combinations | |
GB201301723D0 (en) | Pharmaceutical combinations |